Leavell Investment Management Inc. Makes New $207,000 Investment in Illumina, Inc. (NASDAQ:ILMN)

Leavell Investment Management Inc. purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,548 shares of the life sciences company’s stock, valued at approximately $207,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ILMN. Versant Capital Management Inc grew its holdings in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 146 shares in the last quarter. Golden State Wealth Management LLC purchased a new stake in shares of Illumina during the 4th quarter worth approximately $32,000. TD Private Client Wealth LLC lifted its position in shares of Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after buying an additional 141 shares during the last quarter. Private Trust Co. NA lifted its position in shares of Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after buying an additional 212 shares during the last quarter. Finally, Focused Wealth Management Inc purchased a new stake in shares of Illumina during the 3rd quarter worth approximately $63,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Stephens boosted their price objective on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Canaccord Genuity Group reduced their price objective on shares of Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research report on Friday, February 7th. UBS Group boosted their price objective on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Royal Bank of Canada reduced their price objective on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Finally, Piper Sandler upped their price target on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Illumina currently has a consensus rating of “Moderate Buy” and a consensus target price of $159.45.

Illumina Stock Performance

NASDAQ:ILMN opened at $100.24 on Friday. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a fifty-two week low of $99.35 and a fifty-two week high of $156.66. The stock has a market cap of $15.90 billion, a PE ratio of -13.05 and a beta of 1.10. The firm’s fifty day simple moving average is $133.56 and its 200-day simple moving average is $134.88.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 12.59% and a negative net margin of 27.95%. Analysts expect that Illumina, Inc. will post 4.42 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.